Drug Profile
Research programme: cancer therapeutics - OncBioMune
Alternative Names: PA BC; PA OBC; PGT; PGT OBM; PGT RCLatest Information Update: 28 Aug 2023
Price :
$50
*
At a glance
- Originator Oncbiomune
- Developer OncBioMune
- Class Drug conjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Breast cancer; Colorectal cancer; Lung cancer; Ovarian cancer; Pancreatic cancer; Renal cancer
Most Recent Events
- 28 Aug 2023 No recent reports of development identified for preclinical development in Pancreatic-cancer in USA (Parenteral)
- 28 Apr 2021 No recent reports of development identified for preclinical development in Ovarian-cancer in USA (Parenteral)
- 28 Apr 2021 No recent reports of development identified for preclinical development in Renal-cancer in USA (Parenteral)